CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update
- Progressing broad vaccine development program in collaboration with GSK, with second-generation candidates in Phase 1 clinical trials for COVID-19 and influenza
- CureVac eligible to a €10 million milestone payment from GSK for the initiation of the influenza clinical trial
- Increasing momentum in oncology with access to neoantigen technologies to feed meaningful pipeline of cancer vaccine candidates
- Partnership with myNEO to develop novel mRNA cancer vaccines leveraging myNEO’s advanced platform for tumor antigen discovery and selection
- Cash position of €658.2 million as of March 31, 2022, impacted by wind-down costs for first-generation COVID-19 vaccine program
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the first quarter of 2022 and provided a business update.